<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798433</url>
  </required_header>
  <id_info>
    <org_study_id>2012-12-039</org_study_id>
    <nct_id>NCT01798433</nct_id>
  </id_info>
  <brief_title>STRATEGY for Left Main Coronary Bifurcation Lesion II</brief_title>
  <acronym>STRATEGY-II</acronym>
  <official_title>A Prospective, Multi-center, Randomized Study to Evaluate the Optimal Strategy for Side Branch Treatment in Patients With Left Main Coronary Bifurcation Lesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with unprotected left main (LM) true bifurcation lesion (cohort A), elective
      2-stent strategy is superior to provisional strategy at preventing the occurrence of 12-month
      target lesion failure after percutaneous coronary intervention for bifurcation lesion.

      In patients with unprotected LM non-true bifurcation lesion (cohort B), 1-stent technique
      with mandatory final kissing ballooning is superior to 1-stent technique without kissing
      ballooning at preventing the occurrence of 12-month target lesion failure after percutaneous
      coronary intervention for bifurcation lesion.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 18, 2013</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>12-month</time_frame>
    <description>defined ad a composite of cardiac death, spontaneous MI or target lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12-month</time_frame>
    <description>All deaths were considered cardiac unless a definite non-cardiac cause could be established.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic in-segment restenosis rate</measure>
    <time_frame>9 months</time_frame>
    <description>as measured by 9-month quantitative coronary analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR)</measure>
    <time_frame>12-month</time_frame>
    <description>TVR was defined as repeat revascularization of the target vessel by PCI or bypass graft surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12-month</time_frame>
    <description>Stent thrombosis was assessed based on the definitions of the Academic Research Consortium as definite, probable, or possible stent thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI)</measure>
    <time_frame>12-month</time_frame>
    <description>MI was defined as elevated cardiac enzymes (troponin or MB fraction of creatine kinase, CK-MB) more than the upper limit of the normal value with ischemic symptoms or electrocardiography findings indicative of ischemia that was not related to the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>12-month</time_frame>
    <description>TLR was defined as repeat PCI of the lesion within 5 mm of stent deployment or bypass graft surgery of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periprocedural CK-MB elevation</measure>
    <time_frame>the first 48 hours after PCI</time_frame>
    <description>Periprocedural enzyme elevation was defined as a rise in CK-MB ≥3 times the upper normal limit after the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success rate</measure>
    <time_frame>the first 48 hours after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>immediate after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of contrast dye</measure>
    <time_frame>immediate after PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>One stent technique alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One stent technique alone for non-true LM bifurcation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One stent technique + Elective FKB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One stent technique + Elective FKB for non-true LM bifurcation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Provisional approach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Provisional approach for true LM bifurcation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elective 2-stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elective 2-stent for true LM bifurcation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>One stent technique alone</intervention_name>
    <description>One stent technique alone with drug-eluting stent</description>
    <arm_group_label>One stent technique alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>One stent technique + Elective FKB</intervention_name>
    <description>One stent technique + Elective FKB with drug-eluting stents + balloon</description>
    <arm_group_label>One stent technique + Elective FKB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Provisional approach</intervention_name>
    <description>Provisional approach with drung-eluting stents</description>
    <arm_group_label>Provisional approach</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Elective 2-stent</intervention_name>
    <description>Elective 2-stent with drug-eluting stents</description>
    <arm_group_label>Elective 2-stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥20 years

          2. Left main bifurcation lesion on coronary angiography

          3. Significant myocardial ischemia Main vessel (left main coronary artery and left
             anterior descending artery) and/or side branch (left circumflex artery) diameter
             stenosis &gt; 75%, or diameter stenosis 50-75% with angina and/or objective evidence of
             ischemia in the non-invasive stress test

          4. Significant size of the main branch (left anterior descending artery) and side branch
             (left cirmflex artery) - The reference diameter of both branches ≥ 2.5 mm by visual
             estimation

        Exclusion Criteria:

          1. The patient has a known hypersensitivity or contraindication to any of the following
             medications: Heparin, Aspirin, Clopidogrel, Biolimus

          2. Patients who have received DES implantation in the target lesion prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeon-Cheol Gwon, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2013</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Hyeon-Cheol Gwon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Angioplasty</keyword>
  <keyword>Transluminal</keyword>
  <keyword>Percutaneous Coronary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

